Phase 1b and Phase 2 (combination dose expansion)
Immune-mediated TEAEs, TRAEs
The RP2D for BGB-A333 of 1350 mg was selected for administration alongside tislelizumab in Phase 1b and Phase 2. In Phase 2 (combination dose expansion), only one cohort was opened for dose expansion, with a total of 12 patients treated in the metastatic UC arm.In Phase 1b and Phase 2 (combination dose expansion), all 24 patients (100.0%) experienced a TEAE (Table Immune-mediated TEAEs were reported in five patients (20.8%) (Table TRAEs were reported in 12 patients (50.0%) in total (Table 